Floatz logo

Nivolumab

Pseudomyxoma Peritonei

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pseudomyxoma Peritonei cohort.

Asset / SponsorPhaseRating
Irinotecan
Stony Brook University
Phase 2BB
MITOMYCIN C
Albert Einstein College of Medicine
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Carboplatin
Case Comprehensive Cancer Center
Phase 1CC
Sgn-Stnv
Seagen Inc.
Phase 1CC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →